Metformin, one of the most common prescriptions for the patients with type 2 diabetes25, 26, 27, may reduce cancer risk and suppress tumourigenesis through AMPK-dependent suppression of the mammalian target of rapamycin (mTOR) pathway28, 29, 30, 31, 32, 33, 34. The gene discussed is MTOR; the disease is cancer.